The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer

Accumulating evidence suggests that regulatory B cells (Bregs) play important roles in inhibiting the immune response in tumors. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important molecules that maintain the balance of the immune response and immune tolerance. This study a...

Full description

Bibliographic Details
Main Authors:	Xuejiao Li, Huan Du, Shenghua Zhan, Wenting Liu, Zhangyu Wang, Jing Lan, Longxiang PuYang, Yuqiu Wan, Qiuxia Qu, Sining Wang, Yang Yang, Qin Wang, Fang Xie
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Immunology
Subjects:	sPD-L1 PD-1+ regulator B cells regulator T cell immunosuppression the triple-negative breast cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.830606/full

Similar Items

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
by: Weifang Shao, et al.
Published: (2022-08-01)

Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study
by: Tatiana N. Zabotina, et al.
Published: (2023-12-01)

Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF
by: Chiara Baggio, et al.
Published: (2023-06-01)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
by: Ling Yi, et al.
Published: (2023-03-01)

sPD-1/sPD-L1 proteins in non-small cell lung cancer and esophageal squamous cell carcinoma
by: I. S. Stilidi, et al.
Published: (2022-10-01)

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma
by: Kina Kase, et al.
Published: (2021-03-01)

Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?
by: Andrea Toledo, et al.
Published: (2023-09-01)

Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients
by: Yang Zhang, et al.
Published: (2022-12-01)

Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells
by: QI Lin, et al.
Published: (2022-10-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19
by: Francesco Sabbatino, et al.
Published: (2023-10-01)

Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
by: Janina Świderska, et al.
Published: (2022-01-01)

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
by: Enrico Munari, et al.
Published: (2021-05-01)

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
by: Phyu P. Aung, et al.
Published: (2019-05-01)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
by: Mengyuan Dai, et al.
Published: (2022-11-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
by: Christian Bailly, et al.
Published: (2021-06-01)

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays
by: Wen-Juei Jeng, et al.
Published: (2022-03-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
by: Maria-Luisa del Rio, et al.
Published: (2022-06-01)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
by: Wei Xie, et al.
Published: (2022-07-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves’ and Hashimoto’s diseases
by: Mayumi Kawabata, et al.
Published: (2021-10-01)

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
by: Yinjun He, et al.
Published: (2023-01-01)

Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis
by: Yanrong Wang, et al.
Published: (2023-12-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)

The PD-1/PD-L1 Axis in the Biology of MASLD
by: Rosaria Maria Pipitone, et al.
Published: (2024-03-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
by: Ulrich Krafft, et al.
Published: (2021-05-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods
by: Yuxi Cheng, et al.
Published: (2024-02-01)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023-02-01)

New Immunological Markers in Chromoblastomycosis—The Importance of PD-1 and PD-L1 Molecules in Human Infection
by: Italo N. Cavallone, et al.
Published: (2023-12-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)